Introduction
Ovarian cancer represents the fourth leading cause of cancer-related death for women in the western world (Kohn et al., 2003; . The main reasons for the low survival rate of patients with ovarian cancer are caused by the lack of effective early detection and treatment, as well as the highly metastatic nature of the disease (Gardner et al., 1995) . The pathogenesis of this disease involves widespread dissemination of malignant ovarian epithelium throughout the entire peritoneal cavity (Graves et al., 2004) . Various proteolytic enzymes, including urokinase-type plasminogen activator (uPA) and matrix metalloproteinase (MMP)-2 and MMP-9, are suggested as critical mediators for ovarian cancer metastasis (Kobayashi et al., 1992; Moser et al., 1994; Young et al., 1996; Fishman et al., 1997 Fishman et al., , 2001 . Although MMPs degrade basement membrane, uPA stimulates production of plasmin that degrades various components of extracellular matrix.
Lysophosphatidic acid (1-or 2-acyl-lysophosphatidic acid, LPA) is a lipid mediator that involves in various pathophysiological events, including tumor cell invasion and metastasis (Mills and Moolenaar, 2003) . LPA was first implicated in human oncogenesis, as this biolipid is present at high levels in the ascitic fluid of ovarian cancer patients (Mills et al., 1990; Xu et al., 1995) . Consistently, higher plasma LPA level was reported in ovarian cancer patients compared with patients with benign ovarian masses and healthy subjects (Xu et al., 1998; Bese et al., 2010; Sedlakova et al., 2011) . Further, ovarian cancer cells have been known to secrete LPA to make enriched environment (Fang et al., 2002) . Upon binding to series of cell-surface G-protein-coupled receptors, LPA activates MMP-2 (Fishman et al., 2001) and induces the expression of uPA (Pustilnik et al., 1999) to augment ovarian cancer invasion and metastasis. In addition, our recent data show that LPA aggravates human hepatocellular carcinoma invasion by secreting MMP-9 (Park et al., 2011a) .
Rho-family GTPases influence a plethora cellular activity, including cell polarity and migration, as well as cancer cell growth and progression (Vega and Ridley, 2008) . These GTPases are monomeric 20-30 kDa GTPbinding proteins and function as molecular switches by altering between active GTP-bound and inactive GDPbound forms (Bar-Sagi and Hall, 2000) . One of these Rho GTPases, RhoA, is upregulated in peritoneal metastatic lesions compared with primary tumors of advanced ovarian carcinoma (Dolo et al., 1995) and has an important role in the peritoneal dissemination of ovarian cancer cells (Horiuchi et al., 2008) . RhoA has been known to regulate ovarian cancer cell migration and invasion through focal adhesion assembly (Sawada et al., 2002; Mukai et al., 2003) . However, RhoA was also suggested to augment human prostate cancer cell invasion through activation of transcription factors such as nuclear factor (NF)-kB (Hodge et al., 2003) .
Growing evidence support the critical role of the Rho/ Rho-associated kinase (ROCK) pathway in LPAinduced ovarian cancer cell migration and invasion. LPA induces ovarian cancer cell migration through focal adhesion formation mediated by the Rho/ROCK pathway (Sawada et al., 2002) . In addition, Imamura et al. (2000) suggested that the Rho/ROCK pathway mediates LPA-induced focal adhesion kinase phosphorylation and contributes to LPA-stimulated tumor cell invasion. However, detailed underlying mechanism by which the Rho/ROCK pathway stimulates ovarian cancer cell invasion is remained to be answered. Given that LPA promotes ovarian cancer cell progression through secretion and activation of various proteolytic enzymes, including uPA (Pustilnik et al., 1999) and MMPs (Symowicz et al., 2005) , and that the Rho/ ROCK pathway is implicated in LPA-induced ovarian cancer cell invasion (Imamura et al., 2000) , we hypothesize that LPA-induced Rho activation is implicated in proteolytic enzyme secretion, leading to stimulation of ovarian cancer cell invasion. Indeed, we demonstrate in the present study that LPA induces secretion of proteolytic enzyme MMP-9 and uPA to stimulate ovarian cancer cell invasion. LPA stimulates MMP-9 expression in CAOV-3 and PA-1 cells and uPA expression in SKOV-3 cells. We observed that secretion of these proteolytic enzymes is required for LPAinduced corresponding ovarian cancer cell invasion and that the Rho/ROCK pathway is critical for LPAinduced proteolytic enzyme expression as well as ovarian cancer cell invasion. Further, we demonstrate a critical role of the Rho/ROCK pathway in mediating signal from Ras to NF-kB in LPA-induced proteolytic enzyme expression and cellular invasion. Therefore, our results identify mechanisms by which LPA increases ovarian cancer cell invasion through coordinate activation of a Ras/Rho/ROCK/NF-kB signaling pathway and the proteolytic enzyme secretion.
Results

LPA induces proteolytic enzyme expression
Given that LPA induces secretion and activation of proteolytic enzymes and that MMPs and uPA are important enzymes involved in tumor cell progression, we first determined the effects of LPA on the expression and activation of these proteolytic enzymes in ovarian cancer cells. LPA induced significant increase of MMP-9 mRNA expression in CAOV-3 and PA-1 cells and uPA mRNA expression in SKOV-3 cells (Figure 1a) . However, there was no statistically significant induction of MMP-9 mRNA in SKOV-3 cells and uPA mRNA in CAOV-3 and PA-1 cells. Analysis of proteolytic enzyme activities induced by LPA showed the consistent results: LPA significantly upregulated MMP-9 activity in CAOV-3 and PA-1 but not in SKOV-3 cells (Figure 1b) , whereas LPA-induced uPA activity was observed only in SKOV-3 cells (Figure 1c ). In addition, we did not observe any detectable induction of MMP-2 mRNA expression or its activity by LPA in tested ovarian cancer cells. Therefore, these data suggest that LPA induces lineage-specific proteolytic enzyme secretion from ovarian cancer cells.
MMP-9 and uPA are important for ovarian cancer cell invasion To determine the roles of proteolytic enzymes in LPAinduced ovarian cancer progression, we utilized MMP-9-or uPA-specific small interfering RNA (siRNA) to silence the mRNA expression of corresponding enzymes. Transfection of the cells with MMP-9 or uPA siRNA efficiently attenuated LPA-induced corresponding enzyme mRNA expression (Supplementary data S1), supporting the specificity of the effect of the siRNA. Treatment of the cells with MMP-9 or uPA siRNA also significantly inhibited LPA-induced corresponding ovarian cancer cell invasion: MMP-9 siRNA profoundly reduced LPA-induced invasion in CAOV-3 and PA-1 cells, as uPA siRNA did in SKOV-3 cells (Figure 2 ). More importantly, MMP-9 siRNA did not modulate LPA-induced invasion of SKOV-3 cells, as uPA siRNA did not reduce LPA-induced invasion of CAOV-3 and PA-1 cells. These data strongly suggest that LPAinduced MMP-9 or uPA expression governs the invasion of ovarian cancer cells producing corresponding proteolytic enzymes.
The Rho/ROCK pathway is critical for proteolytic enzyme expression As the Rho/ROCK pathway is important for LPAinduced cancer cell invasion (Imamura et al., 2000) , we first determined the effect of LPA on Rho activation in ovarian cancer cells. LPA dramatically induced Rho activation ( Figure 3a) . However, pretreatment of the cells with a selective pharmacological inhibitor of Rho/ ROCK, Y-27632, efficiently attenuated the LPA-induced proteolytic enzyme mRNA expression from the corresponding ovarian cancer cells: Y-27632 inhibited LPA-induced MMP-9 mRNA expression in CAOV-3 We next utilized a dominant-negative (Rho N19) and a constitutively active (Rho V14) mutant of Rho to confirm the role of Rho in LPA-induced MMP-9 or uPA mRNA expression and ovarian cancer cell invasion. Both ectopic expression of Rho V14 and LPA treatment significantly increased Rho activity (Supplementary data S2). Conversely, transfection with Rho N19 ablated LPA-induced Rho activation, supporting the specificity of the effect of Rho mutants on Rho activation. Utilizing these Rho mutants, we next determine the proteolytic enzyme expression by LPA. Although Rho V14 increased MMP-9 and uPA mRNA expression, Rho N19 dramatically attenuated MMP-9 mRNA expression in CAOV-3 and PA-1 cells and uPA mRNA expression in SKOV-3 cells (Figure 4a ). Consistently, Rho N19 reduced the promoter activity of MMP-9 or uPA in corresponding cells (Figures 4b and c) . More importantly, Rho N19 transfection also significantly inhibited LPA-induced ovarian cancer cell invasion ( Figure 4d ). We confirmed the important role of Rho in LPA-induced proteolytic enzyme mRNA expression and activity by utilizing a selective Rho inhibitor exoenzyme C3 transferase (Supplementary data S3). Collectively, these data suggest a critical role of the Rho/ROCK pathway in LPA-induced proteolytic enzyme expression and cellular invasion.
The Rho/ROCK pathway is a novel mediator connecting Ras to NF-kB Given that the critical role of Ras in LPA-induced ovarian cancer cell migration and invasion (Bian et al., 2004; Li et al., 2005) , we hypothesized that Ras is implicated in proteolytic enzyme expression in ovarian cancer cells. Indeed, we observed that transfection of the cells with constitutively active Ras (Ras V12) significantly increased MMP-9 and uPA mRNA expression ( Figure 5a ). As our present data show that the Rho/ ROCK pathway is important for MMP-9 and uPA expression, we next utilized dominant-negative Ras and questioned the role of Ras in LPA-induced Rho activation. Transfection of the cells with Ras N17 significantly reduced LPA-induced Rho activation (Figure 5b ), suggesting that Ras governs LPA-induced Rho activation. Consistently, Ras N17 abrogated LPAinduced ovarian cancer invasion (Figure 5c ). Therefore, these data suggest a critical role of Ras in Rho activation and the LPA signaling cascade.
We next determined the downstream signaling of Rho/ROCK in LPA-induced proteolytic enzyme expression. Given that NF-kB is one of major transcription factors for both MMP-9 (Farina et al., 1999) and uPA (Novak et al., 1991) expression, we first determined whether NF-kB is necessary for LPA-induced proteolytic enzyme expression in ovarian cancer cells. Treatment of cells with LPA significantly increased MMP-9 and uPA promoter activity in a timedependent manner (Supplementary data S4). We constructed NF-kB mutants of MMP-9 and uPA promoters and found that NF-kB point-mutated MMP-9 and uPA promoters showed a reduced response to stimulation with LPA compared with the constructs made using a wild-type MMP-9 or uPA promoter (Supplementary data S5), suggesting that NF-kB is important for LPA-induced proteolytic enzyme expression.
Next, we utilized a NF-kB promoter to uncover the role of Rho/ROCK pathway in NF-kB activation. LPA significantly induced the NF-kB luciferase activity, which was abrogated by Y-27632 (Figure 6a) . Consistently, Y-27632 treatment profoundly attenuated LPA-induced IkBa phosphorylation (Figure 6b ) as well as NF-kB translocation into the nucleus (Figure 6c ). More importantly, treatment of the cells with a NF-kB inhibitor BAY 11-7082 dramatically reduced LPA-induced MMP-9 and uPA mRNA expression (Figure 6d ) as well as ovarian cancer invasion (Figure 6e ). Collectively, these data strongly suggest that the Rho/ROCK pathway is a critical mediator of Ras signaling to NF-kB in LPA-induced proteolytic enzyme expression and ovarian cancer progression.
Discussion
In our current study, we elucidate the underlying mechanisms by which LPA augments invasion of ovarian cancer cells. We demonstrate that LPA increases ovarian cancer invasion through linage-specific expression of proteolytic enzymes, MMP-9 and uPA. LPA induces uPA in SKOV-3 cells and MMP-9 in CAOV-3 and PA-1 cells to stimulate ovarian cancer cell invasion. In addition, we provide evidence that Ras is involved in LPA-induced Rho activation and ovarian cancer cell invasion. Moreover, our data show that the Rho/ROCK pathway is required for LPA-induced NF- Rho/ROCK for ovarian cancer progression KJ Jeong et al kB activation and proteolytic enzyme expression, as well as ovarian cancer cell invasion. These findings suggest a critical role of LPA in ovarian cancer cell progression through coordinate activation of a Ras/Rho/ROCK/ NF-kB pathway and the important proteolytic enzymes MMP-9 and uPA. LPA has been demonstrated to stimulate invasion through important proteolytic enzyme expression and activation. As one of critical mediators of various cancer cell invasions, MMPs are deeply implicated in LPAinduced cancer cell invasion. Consistent with our recent paper in human hepatocellular carcinoma (Park et al., 2011a, b) , the present data demonstrate that LPA induces and activates MMP-9 but not MMP-2 to augment ovarian cancer cell invasion. On the other hand, we observed that SKOV-3 cells induce uPA expression instead of MMP-9 to stimulate their invasion, as reported previously (Pustilnik et al., 1999) . Therefore, our present results strongly suggest that LPA-induced lineage-specific proteolytic enzyme production confers to corresponding ovarian cancer cell invasion.
Accumulating data support a critical role of the Rho/ ROCK pathway in cancer cell invasion and metastasis. One of the possible mechanisms is through increased polymerization of the actin microfilament cytoskeleton. Indeed, LPA was proposed to accelerate focal adhesion formation through the Rho/ROCK pathway (Sawada et al., 2002) . However, recent findings suggest the other role of the Rho/ROCK pathway in tumor progression through the expression of NF-kB-dependent genes important for invasion (Hansen et al., 1992; Perona et al., 1997; Bond et al., 1998; Cammarano and Minden, 2001; Gnad et al., 2001; Hodge et al., 2003) . Our present data support a contention that upregulation of the Rho/ ROCK pathway by LPA contributes to elevated proteolytic enzyme expression and subsequently cell invasion and metastasis. First, LPA induced Rho activity. Second, inhibition of LPA-induced ROCK by Y-27632 significantly inhibited proteolytic enzyme expression as well as invasive potential of ovarian cancer cell lines. Consistent with these results, overexpression of Rho N19 attenuated LPA-induced MMP-9 and uPA expression, as well as ovarian cancer cell invasion. Finally, LPA-induced Rho activation is required for NF-kB translocation into the nucleus that is implicated in MMP-9 and uPA expression as well as in ovarian cancer cell invasion. Thus, the Rho/ROCK pathway governs for LPA-induced proteolytic enzyme expression and ovarian cancer cell invasion.
Previous report showed that Ras and NF-kB are involved in the induction of uPA expression and invasion of ovarian cancer cells (Li et al., 2005) . Our present data suggest that not only uPA but also MMP-9 expression are closely regulated by Ras and NF-kB in LPA signaling cascade. More importantly, our data suggest the Rho/ROCK pathway as a critical mediator connecting Ras to NF-kB in LPA-induced proteolytic enzyme secretion as well as ovarian cancer invasion. In support of our results, recent studies showed that a Ras/Rho signaling is implicated in NF-kB activation and MMP-9 expression (Chang et al., 2010) . Moreover, our unpublished data show that a Gi-selective inhibitor pertussis toxin significantly inhibits LPA-induced Rho activation, supporting the important role of Gi in Ras and Rho activation in LPA signaling axis (data not shown). In view of our present data, we present a working model (Figure 7 ) in which Gi and Ras are required for LPA-induced Rho activation and proteolytic enzyme expression.
In conclusion, our results demonstrate that LPA increases ovarian cancer cell invasion through a Ras/ Rho/ROCK signaling pathway and subsequent activation of NF-kB and production of proteolytic enzymes MMP-9 and uPA. Therefore, Ras, Rho/ROCK, MMP-9 and uPA may represent useful targets to reduce invasion and metastasis of ovarian cancer cells.
Materials and methods
Reagents LPA was obtained from Avanti Polar Lipids (Alabaster, AL, USA). Y-27632 and BAY 11-7082 were obtained from Calbiochem (Darmstadt, Germany). Cell-permeable exoenzyme C3 transferase was from Cytoskeleton Inc. (Denver, CO, USA). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA, USA). All other reagents used were of the purest grade available.
Cell culture
All ovarian cancer cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). SKOV-3 and CAOV-3 cells were maintained in RPMI 1640 supplemented with 5% fetal bovine serum and 1% penicillin/streptomycin. PA-1 cells were maintained in EMEM supplemented with 5% fetal bovine serum in a humidified atmosphere containing 5% CO 2 at 37 1C.
siRNA transfection siRNAs of MMP-9 and uPA were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Negative control siRNA were obtained from Invitrogen. Cells were transfected with siRNA by utilizing Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions.
RT-PCR quantification
Quantitative RT-PCR was performed to quantify MMP-9, uPA and glyceraldehyde-3-phosphate dehydrogenase. Total cellular RNA was isolated from cultured cells using Trizol (Invitrogen), and 1 mg of RNA was reverse transcribed using oligo (dT) and M-MLV reverse transcriptase (Promega, Madison, WI, USA) according to the manufacturer's protocol. The complementary DNAs were amplified using an iQ5 RealTime PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) with the following primer sets: MMP-9, 5 0 -GTGC CATGTAAATCCCCACT-3 0 (forward) and 5 0 -CTCCACTCC TCCCTTTCCTC-3 0 (reverse); uPA, 5 0 -GTGGCCAAAAGAC TCTGAGG-3 0 (forward) and 5 0 -GCCGTACATGAAGCAG TGTG-3 0 (reverse); and glyceraldehyde-3-phosphate dehydrogenase, 5
0 -ACAGTCAGCCGCATCTTCTT-3 0 (forward) and 5 0 -ACGACCAAATCCGTTGACTC-3 0 (reverse). Reactions were performed as described previously (Park et al., 2011a, b) .
Immunoblotting Cells lysates were prepared as described (Lee et al., 2006) . Antibodies for Rho and glyceraldehyde-3-phosphate dehydrogenase were from Upstate Biotechnology (Lake Placid, NY, USA) and Santa Cruz Biotechnology Inc., respectively. The immunoreactive bands were visualized by ECL (LabFrontier Ltd, Seoul, Korea) using ImageQuant 300 (GE Healthcare, Buckinghamshire, UK).
Rho activation assay
To assess Rho activation, the amount of RhoA-GTP bound to the Rhotekin RBD was determined using the Rho Activation Assay Kit (Upstate Biotechnology) according to the manufacturer's instructions. Briefly, the cells were cultured in 150 mm tissue culture plate to confluent, followed by serum starvation and subsequently treatment with pharmacological inhibitors and LPA. Protein concentration was determined and equal amounts of protein were incubated with RBDagarose for 45 min at 4 1C. Agarose beads were washed three times with lysis/wash buffer, resuspended in Laemmli sample buffer and boiled for 5 min. Lysates were immunoblotted with anti-RhoA.
In vitro invasion and migration assay In vitro invasion assay was performed with invasion assay kit with Matrigel-coated inserts (BD Biosciences, San Jose, CA, USA) as described previously (Park et al., 2011a) . Volume of 1 Â 10 5 cells/well was added to the upper compartment of the invasion chamber with or without pharmacological inhibitors. To the lower compartment, we added serum-free conditioned medium with or without LPA. After incubation for 24 h at 37 1C, filters were fixed and stained with Diff-Quik reagents (Dade Behring Inc., Newark, DE, USA). The values obtained were calculated using the number of invaded cells from three filters.
Cell migration assays were performed in triplicates using a 48-well microchemotaxis chamber as described previously (Seo et al., 2010) . Briefly, trypsinized cells were resuspended at a density of 2 Â 10 6 cells/ml in RPMI 1640 with 0.1% bovine serum albumin. Type I collagen-coated polyvinyl pyrrolidinefree polycarbonate filters with 8 mm pore membranes (Neuro Probe, Gaithersburg, MD, USA) were used in these modified Boyden chambers. After incubation for 6 h, the membrane was fixed and stained with Diff-Quik reagents. Cell migration was quantitated by counting the number of cells in five random high-power fields for each replicate ( Â 400) with a light microscope.
Gelatin zymography assay
The concentrated conditioned medium was electrophoresed by 10% SDS-polyacrylamide gel electrophoresis gel containing 0.1% (w/v) gelatin. After washing with 2.5% Triton X-100, the gels were incubated in 10 mM CaCl 2 , 0.01% NaN 3 and 50 mM Tris-HCl (pH 7.5) for overnight at 37 1C. The gel was stained with 0.25% Coomassie blue for 1 h and destained in methanol/ acetic acid. Gelatinolytic activity was manifested as horizontal white bands on a blue background.
uPA activity assay The analysis of uPA activity was determined using uPA Activity Assay Kit (Chemicon, Temecula, CA, USA) according to the manufacturer's protocol.
Plasmids and site-direct mutagenesis
Wild type of MMP-9 promoter and NF-kB-mutated MMP-9 promoter were kindly provided by Dr Taeg Kyu Kwon (Keimyung University, Daegu, South Korea) and were described previously (Woo et al., 2004) . uPA promoter in luciferase reporter gene plasmid pGL2 basic was kindly provided by Dr Gordon B. Mills (University of Texas MD Anderson Cancer Center, Houston, TX, USA). Point mutation of NF-kB binding site to the uPA promoter was generated by double-stranded, site-directed mutagenesis kit from Stratagene (La Jolla, CA, USA) with following primers: NF-kB (5 0 -GGGGGGGATCCTCTAGAGTCAATTCGAGCT-3 0 and 5 0 -GGGGGGGATTAGCTAGAGTCAATTCGAGCT-3 0 ).
Luciferase assay
The cells were cotransfected with 1 mg of promoter luciferase reporter constructs and 1 mg of b-galactosidase reporter plasmid by the Lipofectamine 2000 transfection reagent, followed by LPA treatment in serum-free medium for 24 h. Luciferase activities and b-galactosidase activity were assayed by using the luciferase and b-galactosidase enzyme assay system (Promega). Luciferase activity was normalized with the b-galactosidase activity in cell lysate and calculated as an average of three independent experiments.
NF-kB translocation assay
The cells were grown on coverslips in 12-well plates. After 24 h, the cells were serum starved and pretreated with Y-27632 for 1 h, followed by LPA stimulation for 24 h. Then, the cells were washed three times with phosphate-buffered saline, fixed with 4% formaldehyde, blocked in fresh 1% bovine serum albumin/ phosphate-buffered saline for 1 h and stained with monoclonal anti-NF-kB (1:100; Santa Cruz Biotechnology Inc.) and Cy2-conjugated goat anti-rabbit IgG (1:250; Jackson Immuno Research, West Grove, PA, USA). The nuclei of the cells were counterstained with 4 0 ,6 0 -diamidino-2-phenylindole dihydrochloride (1:1000; Molecular Probes, Carlsbad, CA, USA). Stained cells were visualized with the IX71 fluorescence microscope (Olympus, Tokyo, Japan).
Statistics
Data are shown as means ± s.d. Differences between two groups were assessed using the Student's t-test. Differences among three or more groups were evaluated by analysis of variance, followed by Bonferroni multiple comparison tests.
